XML 30 R9.htm IDEA: XBRL DOCUMENT
v3.22.1

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS | 3 Months Ended
--- | ---
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS | OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS Composition of Certain Financial Statement Captions (in millions) Components of selected captions in the consolidated condensed balance sheets consisted of the following:
| March 31, 2022 |  | December 31, 2021
Inventories |  |  |
Raw materials | $ | 137.4 |  |  | $ | 132.8 |
Work in process | 150.6 |  |  | 164.3 |
Finished products | 442.6 |  |  | 429.6 |
| $ | 730.6 |  |  | $ | 726.7 |
At March 31, 2022 and December 31, 2021, $116.2 million and $125.8 million, respectively, of the Company's finished products inventories were held on consignment.
| March 31, 2022 |  | December 31, 2021
Accrued and other liabilities |  |  |
Employee compensation and withholdings | $ | 221.7 |  |  | $ | 319.7 |
Taxes payable | 93.1 |  |  | 30.6 |
Property, payroll, and other taxes | 69.2 |  |  | 68.9 |
Research and development accruals | 56.5 |  |  | 58.2 |
Accrued rebates | 78.4 |  |  | 77.0 |
Fair value of derivatives | 3.8 |  |  | 3.9 |
Accrued marketing expenses | 16.8 |  |  | 20.1 |
Legal and insurance (a) | 78.3 |  |  | 79.1 |
Accrued relocation costs | 27.6 |  |  | 26.2 |
Accrued professional services | 14.2 |  |  | 11.9 |
Accrued realignment reserves | 19.4 |  |  | 19.1 |
Other accrued liabilities | 88.2 |  |  | 87.6 |
| $ | 767.2 |  |  | $ | 802.3 |
_______________________________________ (a) On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries to, among other things, settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. As of March 31, 2022, $50.0 million was accrued in "Accrued and other liabilities" and $181.3 million was accrued in "Litigation settlement accrual" on the consolidated condensed balance sheet. Supplemental Cash Flow Information (in millions)
| Three Months Ended March 31,
| 2022 |  | 2021
Cash paid during the year for: |  |  |
Amounts included in the measurement of lease liabilities: |  |  |
Operating cash flows from operating leases | $ | 7.6 |  |  | $ | 7.7 |
Non-cash investing and financing transactions: |  |  |
Right-of-use assets obtained in exchange for new lease liabilities | $ | 6.4 |  |  | $ | 3.5 |
Capital expenditures accruals | $ | 23.8 |  |  | $ | 36.4 |
Cash, Cash Equivalents, and Restricted Cash (in millions)
| March 31, 2022 |  | December 31, 2021 |
Cash and cash equivalents | $ | 1,030.9 |  |  | $ | 862.8 |  |
Restricted cash included in other current assets | 1.3 |  |  | 1.5 |  |
Restricted cash included in other assets | 3.1 |  |  | 3.1 |  |
Total cash, cash equivalents, and restricted cash | $ | 1,035.3 |  |  | $ | 867.4 |  |
Amounts included in restricted cash primarily represent funds placed in escrow related to litigation.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration